Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2608
Source ID: NCT00865592
Associated Drug: Dutogliptin
Title: Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus
Acronym:
Status: TERMINATED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus|Type 2 Diabetes
Interventions: DRUG: dutogliptin
Outcome Measures: Primary: To demonstrate safety and tolerability of dutogliptin, Two years | Secondary: To demonstrate maintenance or lowering of HbA1c, Two years|To demonstrate maintenance or lowering of fasting blood glucose, Two years
Sponsor/Collaborators: Sponsor: Phenomix | Collaborators: Forest Laboratories
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 450
Study Type: INTERVENTIONAL
Study Designs: Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2009-03
Completion Date: 2011-03
Results First Posted:
Last Update Posted: 2010-08-11
Locations: Norwalk, California, United States|Orange, California, United States|Santa Ana, California, United States|Daytona Beach, Florida, United States|Kissimmee, Florida, United States|Atlanta, Georgia, United States|Phenomix Investigational Site 663, Honolulu, Hawaii, United States|Brockton, Massachusetts, United States|St. Louis, Missouri, United States|Cincinnati, Ohio, United States|El Paso, Texas, United States|San Antonio, Texas, United States|Norfolk, Virginia, United States|Phenomix Investigational Site 103, Buenos Aires, Argentina|Phenomix Investigational Site 110, Buenos Aires, Argentina|Phenomix Investigational Site 111, Buenos Aires, Argentina|Phenomix Investigational Site 106, Caba, Argentina|Phenomix Investigational Site 112, Corrientes, Argentina|Phenomix Investigational Site 102, Paraná, Argentina|Bangalore, Karnataka, India|Chennai, Tamil Nadu, India|Gulbarga, Karnataka, India|Hyderabad, Andhara Pradesh, India|Mumbai, Maharashtra, India|Nagpur, Maharashtra, India|Nashik, Maharashtra, India|Navi Mumbai, Maharashtra, India|Pune, Maharashtra, India|Phenomix Investigational Site 403, Kuching, Sarawak, Malaysia|Kelantan, Malaysia|Kuala Lumpur, Malaysia|Perak, Malaysia|Phenomix Investigational Site 404, Putrajaya, Malaysia|Sarawak, Malaysia|Phenomix Investigational Site 604, Arequipa, Peru|Phenomix Investigational Site 606, Lambayeque, Peru|Phenomix Investigational Site 600, Lima, Peru|Phenomix Investigational Site 601, Lima, Peru|Phenomix Investigational Site 602, Lima, Peru|Phenomix Investigational Site 609, Lima, Peru|Phenomix Investigational Site 703, Cebu City, Philippines|Manila, NCR, Philippines|Quezon City, NCR, Philippines|San Juan, NCR, Philippines|Phenomix Investigational Site 802, Brasov, Romania|Phenomix Investigational Site 806, Brasov, Romania|Phenomix Investigational Site 800, Bucharest, Romania|Phenomix Investigational Site 803, Bucharest, Romania|Phenomix Investigational Site 805, Bucharest, Romania|Phenomix Investigational Site 807, Bucharest, Romania|Phenomix Investigational Site 804, Galati, Romania|Phenomix Investigational Site 801, Ploieşti, Romania|Phenomix Investigational Site 808, Sibiu, Romania|Phenomix Investigational Site 551, Ivano-Frankivsk, Ukraine|Phenomix Investigational Site 557, Kharkiv, Ukraine|Phenomix Investigational Site 564, Kharkiv, Ukraine|Phenomix Investigational Site 550, Kharkov, Ukraine|Phenomix Investigational Site 555, Kiev, Ukraine|Phenomix Investigational Site 556, Kiev, Ukraine|Phenomix Investigational Site 562, Kiev, Ukraine|Phenomix Investigational Site 563, Kiev, Ukraine|Phenomix Investigational Site 554, Kylv, Ukraine|Phenomix Investigational Site 565, Lutsk, Ukraine|Phenomix Investigational Site 553, Lviv, Ukraine|Phenomix Investigational Site 561, Poltava, Ukraine|Phenomix Investigational Site 560, Simferopol, Ukraine|Phenomix Investigational Site 559, Vinnitsa, Ukraine|Phenomix Investigational Site 552, Zaporzhzhia, Ukraine
URL: https://clinicaltrials.gov/show/NCT00865592

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress